Can Synjardy (empagliflozin and metformin) cause leukocytosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Synjardy (empagliflozin and metformin) is not typically associated with leukocytosis as a common side effect. While both components of this medication can cause various side effects, an increase in white blood cell count is not among the frequently reported adverse reactions. However, it's essential to consider that empagliflozin, one component of Synjardy, is associated with an increased risk of urinary tract and genital infections, which could potentially lead to secondary leukocytosis as part of the body's immune response to infection rather than as a direct effect of the medication itself 1. If a patient taking Synjardy develops leukocytosis, healthcare providers should investigate other potential causes such as infections, inflammation, stress responses, or other medications the patient may be taking. The mechanism of action for both empagliflozin (SGLT2 inhibitor that increases glucose excretion through the kidneys) and metformin (which decreases hepatic glucose production and improves insulin sensitivity) does not directly suggest an impact on white blood cell production or regulation. Some studies have explored the effects of empagliflozin and metformin on inflammatory responses and glucose control, but these do not directly address the question of leukocytosis 2, 3, 4, 5. Any unexplained persistent leukocytosis in a patient taking Synjardy should prompt medical evaluation to determine the underlying cause. Key points to consider include:

  • The direct effects of Synjardy on white blood cell count are not well-documented as a common side effect.
  • Empagliflozin's association with increased risk of infections could indirectly lead to leukocytosis.
  • Investigation into other causes of leukocytosis is necessary if it occurs in patients taking Synjardy.
  • The most recent and highest quality studies do not provide direct evidence linking Synjardy to leukocytosis, with the most relevant study being from 1, which discusses the modulation of inflammatory gene expression by empagliflozin and metformin.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.